Fresenius Medical Care Annual General Meeting: Company makes significant progress in its Transformation Efforts and confirms its ambitious 2024 Growth Targets
Rhea-AI Summary
Fresenius Medical Care announced significant progress in its transformation efforts at its Annual General Meeting on May 16, 2024. Shareholders approved a 6% increase in dividends to 1.19 euros and a new compensation system for the Management Board. The company confirmed its ambitious growth targets for 2024. CEO Helen Giza highlighted top- and bottom-line growth for 2023, exceeding operating income expectations. The Management Board's transformation program, FME25, is ahead of schedule. The company aims to focus on disciplined execution and value creation in 2024. A substantial majority of shareholders approved various proposals, showing strong support for the company's direction.
Positive
- Shareholders approved a 6% increase in dividends to 1.19 euros.
- New compensation system for the Management Board approved.
- Confirmed ambitious growth targets for 2024.
- Exceeded operating income outlook for 2023, raised twice.
- FME25 transformation program is ahead of schedule.
- High shareholder approval: 96.97% for dividends, 87.58% for compensation system.
- Strong support for Management and Supervisory Boards: over 98% approval.
Negative
- High expectations for 2024 may increase pressure on management to deliver.
- Dependence on successful execution of transformation plans to meet growth targets.
- Potential risks if the FME25 program falls behind schedule in the future.
News Market Reaction – FMS
In the trading session that priced this news, FMS declined 0.09%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
- Today's Annual General Meeting was the first one following the change in legal form completed in November 2023
- Shareholders voted in favor of the proposed dividend of
1.19 euros , representing an increase of around 6 percent compared to the previous year - New compensation system for Management Board approved
- Ambitious growth targets for 2024 confirmed
BAD HOMBURG,
At today's Annual General Meeting, Michael Sen, Chairman of the Supervisory Board of Fresenius Medical Care AG, said: "Fresenius Medical Care has made significant progress in 2023. The consistent implementation of the transformation program is beginning to pay off. The deconsolidation and the independence are providing Fresenius Medical Care with everything it needs to further strengthen its position in the dialysis market and to realize its full potential."
Michael Sen added: "On behalf of the Supervisory Board, I would like to thank the members of the Management Board under the leadership of CEO Helen Giza for their trusting cooperation and very good performance in the past financial year. The newly composed management team has the necessary expertise, energy, and experience to take the company forward in the interests of patients, employees, and shareholders."
Helen Giza, CEO of Fresenius Medical Care AG, said: "For 2023, we delivered top- and bottom-line growth, and exceeded our operating income outlook that we raised twice. Our FME25 transformation program is ahead of schedule and our portfolio optimization program is well underway. All our achievements mark a highly successful conclusion to an exceptional year of transformation and turnaround efforts."
"Turning to 2024, this year is being spent in singular focus on disciplined execution and value creation. While 2023 was a year of level-setting, 2024 is one of momentum-building," said Giza. The CEO thanked employees for their dedication and commitment to ensuring high-quality care for patients worldwide.
A significant majority of 96.97 percent of shareholders approved the dividend proposal for fiscal year 2023 of
The shareholders also approved, with a majority of 87.58 percent, the new Management Board's compensation system.
With a majority of 99.49 percent, the shareholders also approved the update to the Supervisory Board's remuneration.
The Management Board and the Supervisory Board were discharged for the year 2023 with majorities of 98.71 percent and 98.42 percent, respectively.
At the Annual General Meeting, 88.39 percent of the share capital was represented.
About Fresenius Medical Care:
Fresenius Medical Care is the world's leading provider of products and services for people with kidney diseases, of whom approximately 4.1 million patients worldwide receive regular dialysis treatment. Through its network of 3,862 dialysis centers, Fresenius Medical Care provides dialysis treatment for approximately 325,000 patients worldwide and is the leading provider of dialysis products such as dialysis machines and dialyzers. Fresenius Medical Care is listed on the Frankfurt Stock Exchange (FME) and the New York Stock Exchange (FMS).
For further information, please visit www.freseniusmedicalcare.com/de.
Legal Disclaimer:
This communication contains forward-looking statements, which are subject to various risks and uncertainties. Future results may differ significantly from the currently expected results due to various factors such as changes in the business, economic, and competitive situation, changes in laws, regulatory approvals, the impact of the Covid-19 pandemic, results of clinical studies, exchange rate fluctuations, uncertainties regarding litigation or investigative proceedings, and the availability of financial resources. These and other risks and uncertainties are described in detail in the reports of Fresenius Medical Care AG filed with the
Media Contact
Christine Peters
T +49 160 60 66 770
christine.peters@freseniusmedicalcare.com
Contact for Analysts and Investors
Dr. Dominik Heger
T +49 6172 609 2601
dominik.heger@freseniusmedicalcare.com
www.freseniusmedicalcare.com/de
View original content to download multimedia:https://www.prnewswire.com/news-releases/fresenius-medical-care-annual-general-meeting-company-makes-significant-progress-in-its-transformation-efforts-and-confirms-its-ambitious-2024-growth-targets-302147875.html
SOURCE Fresenius Medical Care Holdings, Inc.